Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Nonmyeloablative Transplant for Sickle Cell Disease Does Not Lead to Kidney Dysfunction Post-HSCT

Emily Limerick, Santosh L. Saraf, Neal Jeffries, Farah O'Boyle, Clarissa Diamantidis, Yuliya Lokhnygina, Matthew M. Hsieh, Josu de la Fuente, Courtney D. Fitzhugh

Blood (2021) 138 (Supplement 1): 984.

DOI: https://doi.org/10.1182/blood-2021-153230

Published: 2021

Journal Articles

Renal Function Is Preserved after Hematopoietic Stem Cell Transplantation for Sickle Cell Disease

Emily Limerick, MD, Neal Jeffries, PhD, Clarissa Diamantidis, MD, Yuliya Lokhnygina, PhD, Matthew M. Hsieh, MD, Courtney D. Fitzhugh, MD

Blood (2020) 136 (Supplement 1): 58–59.

DOI: https://doi.org/10.1182/blood-2020-142630

Published: 2020

Journal Articles

Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation

Jack Y. Ghannam, Xin Xu, Irina Maric, Laura Dillon, Yuesheng Li, Matthew M. Hsieh, Christopher S. Hourigan, Courtney D. Fitzhugh

Blood (2020) 135 (14): 1185–1188.

DOI: https://doi.org/10.1182/blood.2019004001

Published: 2020

Journal Articles

Selective Proliferation of Gene-Modified Human Erythroid Cells with Truncated Erythropoietin Receptors

Naoya Uchida, MD PhD, Anna Shvygin, Lydia Raines, Juan Jesus J. Haro Mora, PhD, Selami Demirci, PhD, Matthew M. Hsieh, MD, John F Tisdale, MD

Blood (2017) 130 (Supplement 1): 3338.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3338.3338

Published: 2017

Journal Articles

At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT

Courtney D. Fitzhugh, Stefan Cordes, Tiffani Taylor, Wynona Coles, Katherine Roskom, Mary Link, Matthew M. Hsieh, John F. Tisdale

Blood (2017) 130 (17): 1946–1948.

DOI: https://doi.org/10.1182/blood-2017-03-772392

Published: 2017

Includes: Supplemental data

Journal Articles

At Least 20% Donor Myeloid Chimerism Is Necessary to Reverse the Sickle Phenotype after Allogeneic Hematopoietic Stem Cell Transplantation

Courtney D. Fitzhugh, MD, Matthew M. Hsieh, MD, Stefan Cordes, MD, Tiffani Taylor, PA, Wynona Coles, MPH, Katherine Roskom, RN, John F. Tisdale, MD

Blood (2016) 128 (22): 2483.

DOI: https://doi.org/10.1182/blood.V128.22.2483.2483

Published: 2016

Journal Articles

Development of a New Generation, Forward-Oriented Therapeutic Vector for Hemoglobin Disorders

Naoya Uchida, MD PhD, Matthew M. Hsieh, MD, Aylin C Bonifacino, Allen E Krouse, Mark E Metzger, Robert E Donahue, John F. Tisdale, MD

Blood (2016) 128 (22): 1172.

DOI: https://doi.org/10.1182/blood.V128.22.1172.1172

Published: 2016

Journal Articles

Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease

Julie Kanter, MD, Mark C. Walters, MD, Matthew M. Hsieh, MD, Lakshmanan Krishnamurti, MD, Janet Kwiatkowski, MD, Rammurti T Kamble, MD, Christof von Kalle, MD, Frans A. Kuypers, PhD, Marina Cavazzana, MD PhD, Philippe Leboulch, MD, Marcelyne Joseney-Antoine, Mohammed Asmal, MD PhD, Alexis A. Thompson, MD MPH, John F. Tisdale, MD

Blood (2016) 128 (22): 1176.

DOI: https://doi.org/10.1182/blood.V128.22.1176.1176

Published: 2016

Journal Articles

Immunohematologic Complications after Nonmyeloablative Hematopoietic Progenitor Cell Transplantation in Patients with Sickle Cell Disease

Elizabeth S. Allen, MD, Matthew M. Hsieh, MD, Courtney D. Fitzhugh, MD, Harvey G. Klein, MD, John F. Tisdale, MD, Willy A. Flegel

Blood (2016) 128 (22): 3404.

DOI: https://doi.org/10.1182/blood.V128.22.3404.3404

Published: 2016

Journal Articles

A Novel Recombinant Eklf-GATA1 Fusion Protein Reduces Sickling of Erythrocytes Cultured from CD34 + Cells with Sickle Cell Disease

Jianqiong Zhu, Kyung Chin, Wulin Aerbajinai, MD PhD, Chutima Kumkhaek, PhD, Hongzhen Li, Matthew M. Hsieh, MD, Courtney D. Fitzhugh, MD, Griffin P. Rodgers, MD

Blood (2016) 128 (22): 3506.

DOI: https://doi.org/10.1182/blood.V128.22.3506.3506

Published: 2016

Journal Articles

Hematopoietic Progenitor Cell Mobilization In Response To G-CSF Is More Robust In Healthy African American Compared To Caucasian Donors

Sandhya R. Panch, MD, MPH, Yu Ying Yau, RN, Courtney Fitzhugh, MD, Matthew M. Hsieh, MD, John F. Tisdale, MD, Charles D. Bolan, Jr., MD, Susan F. Leitman, MD

Blood (2013) 122 (21): 696.

DOI: https://doi.org/10.1182/blood.V122.21.696.696

Published: 2013

Journal Articles

Peripheral Blood As a Source Of Cells For Regenerative Medicine Applications In Sickle Cell Disease

Atsushi Fujita, MD, PhD, Courtney D. Fitzhugh, MD, Matthew M. Hsieh, MD, John F. Tisdale, MD, Naoya Uchida, MD, PhD

Blood (2013) 122 (21): 2209.

DOI: https://doi.org/10.1182/blood.V122.21.2209.2209

Published: 2013

Journal Articles

Assessment Of The Endocrine Function Of Patients With Sickle Cell Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Helen Gharwan, MD, DSc, Courtney Fitzhugh, MD, Mary Link, RN, Wynona Coles, RRT, Deborah Citrin, MD, John F. Tisdale, MD, Matthew M. Hsieh, MD

Blood (2013) 122 (21): 4646.

DOI: https://doi.org/10.1182/blood.V122.21.4646.4646

Published: 2013

Journal Articles

Therapeutic Hydroxyurea Dosing Is Associated With Decreased Organ Damage and Longer Survival In Adults With Sickle Cell Anemia

Courtney Fitzhugh, MD, Darlene Allen, MT(ASCP), Wynona Coles, RRT, Michael Ring, MD, Xiongce Zhao, PhD, Matthew M. Hsieh, MD, James G Taylor, MD

Blood (2013) 122 (21): 2228.

DOI: https://doi.org/10.1182/blood.V122.21.2228.2228

Published: 2013

Journal Articles

MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34 + cells through the Raf/MEK/ERK pathway

Chutima Kumkhaek, Wulin Aerbajinai, Wenli Liu, Jianqiong Zhu, Naoya Uchida, Roger Kurlander, Matthew M. Hsieh, John F. Tisdale, Griffin P. Rodgers

Blood (2013) 121 (16): 3216–3227.

DOI: https://doi.org/10.1182/blood-2011-10-385252

Published: 2013

Includes: Supplemental data

Journal Articles

High Dose Plerixafor Is Safe and Mobilizes Higher Numbers of CD34+ Cells Compared with Standard Dose Plerixafor

Jeremy M Pantin, MB.BS., Xin Tian, Ph.D., Matthew M. Hsieh, MD, Lisa Cook, RN, BSN, Theresa Donohue, MHS, PA-C, Elena Cho, RN MSN, Aleah Smith, Robert Reger, Thomas Trischman, PhD, Hanh Khuu, MD, Richard Childs, MD

Blood (2012) 120 (21): 585.

DOI: https://doi.org/10.1182/blood.V120.21.585.585

Published: 2012

Journal Articles

Infusion of hemolyzed red blood cells within peripheral blood stem cell grafts in patients with and without sickle cell disease

Courtney D. Fitzhugh, Hayato Unno, Vincent Hathaway, Wynona A. Coles, Mary E. Link, R. Patrick Weitzel, Xiongce Zhao, Elizabeth C. Wright, David F. Stroncek, Gregory J. Kato, Matthew M. Hsieh, John F. Tisdale

Blood (2012) 119 (24): 5671–5673.

DOI: https://doi.org/10.1182/blood-2011-11-392654

Published: 2012

Includes: Supplemental data

Journal Articles

TRIM5α Variation Affects Lentiviral Transduction Efficiency for Long-Term Hematopoietic Repopulating Cells in a Rhesus Stem Cell Transplantation Model

Naoya Uchida, Matthew M. Hsieh, MD, Aylin C. Bonifacino, Sandra D. Price, Allen E. Krouse, Mark E. Metzger, Robert E. Donahue, John F. Tisdale

Blood (2011) 118 (21): 2056.

DOI: https://doi.org/10.1182/blood.V118.21.2056.2056

Published: 2011

Journal Articles

High Transgene Expression Rates After Extended Follow up Among Rhesus Macaque Recipients of Autologous Hematopoietic Stem Cells Transduced with a Modified HIV1-Based Lentiviral Vector

Naoya Uchida, Phillip W. Hargrove, M.S., Coen J. Lap, MD, Oswald Phang, Jr., Aylin C. Bonifacino, Allen E. Krouse, Mark E. Metzger, Anh-Dao Nguyen, Matthew M. Hsieh, MD, Tyra G. Wolfsberg, Robert E. Donahue, Derek A. Persons, MD, PhD, John F. Tisdale

Blood (2011) 118 (21): 3118.

DOI: https://doi.org/10.1182/blood.V118.21.3118.3118

Published: 2011

Journal Articles

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Patients with Severe Sickle Cell Disease (SCD)

Matthew M Hsieh, Courtney D Fitzhugh, MD, R. Patrick Weitzel, PhD, Wynona Coles, M Beth Link, John F. Tisdale

Blood (2011) 118 (21): 10.

DOI: https://doi.org/10.1182/blood.V118.21.10.10

Published: 2011

NARROW

Nonmyeloablative Transplant for Sickle Cell Disease Does Not Lead to Kidney Dysfunction Post-HSCT

Renal Function Is Preserved after Hematopoietic Stem Cell Transplantation for Sickle Cell Disease

Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation

Selective Proliferation of Gene-Modified Human Erythroid Cells with Truncated Erythropoietin Receptors

At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT

At Least 20% Donor Myeloid Chimerism Is Necessary to Reverse the Sickle Phenotype after Allogeneic Hematopoietic Stem Cell Transplantation

Development of a New Generation, Forward-Oriented Therapeutic Vector for Hemoglobin Disorders

Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease

Immunohematologic Complications after Nonmyeloablative Hematopoietic Progenitor Cell Transplantation in Patients with Sickle Cell Disease

A Novel Recombinant Eklf-GATA1 Fusion Protein Reduces Sickling of Erythrocytes Cultured from CD34 + Cells with Sickle Cell Disease

Hematopoietic Progenitor Cell Mobilization In Response To G-CSF Is More Robust In Healthy African American Compared To Caucasian Donors

Peripheral Blood As a Source Of Cells For Regenerative Medicine Applications In Sickle Cell Disease

Assessment Of The Endocrine Function Of Patients With Sickle Cell Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Therapeutic Hydroxyurea Dosing Is Associated With Decreased Organ Damage and Longer Survival In Adults With Sickle Cell Anemia

MASL1 induces erythroid differentiation in human erythropoietin-dependent CD34 + cells through the Raf/MEK/ERK pathway

High Dose Plerixafor Is Safe and Mobilizes Higher Numbers of CD34+ Cells Compared with Standard Dose Plerixafor

Infusion of hemolyzed red blood cells within peripheral blood stem cell grafts in patients with and without sickle cell disease

TRIM5α Variation Affects Lentiviral Transduction Efficiency for Long-Term Hematopoietic Repopulating Cells in a Rhesus Stem Cell Transplantation Model

High Transgene Expression Rates After Extended Follow up Among Rhesus Macaque Recipients of Autologous Hematopoietic Stem Cells Transduced with a Modified HIV1-Based Lentiviral Vector

Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Patients with Severe Sickle Cell Disease (SCD)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only